Screener / SEC EDGAR /CIK 0001727196 /10-K filed Mar 3, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Scholar Rock Holding Corp SRRK

Compare with peers Embed
SEC comment letters, last 20 years

1 review of SRRK's filings by SEC staff

UPLOAD and CORRESP
Reviews 1 latest letter Apr 19, 2018
Questions asked 18 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 2 UPLOAD
  2. 2. Questions in them 18 numbered comments
  3. 3. Company replies 4 CORRESP
  4. 4. Reviews closed 0 of 1 closing letter

Form S-1

2018-04-19 to 2018-05-21 · 18 questions · 2 letters from the SEC, 4 from the company
No closing letter
Results discussion (MD&A)Risk factorsRevenue
Prospectus Summary · Overview, page 1
SEC asked (1)
Please balance your statement that you are focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role with the fact that you are a clinical stage biopharmaceutical company and that your lead product candidate has yet to begin Phase 1 clinical development.
SRRK answered
A bona fide estimate of the range of the offering price for the shares of the Company’s common stock offered by the Registration Statement (before giving effect to a contemplated reverse stock split of the Company’s common stock in connection with the offering), and a discussion of the factors that the Company believes led to the increase in the value of its common stock between the recent valuations of its common stock and the estimated price range for the offering, attached hereto as Exhibit A.
Read in the reply
Prospectus Summary · Overview, page 1
SEC asked (2)
We note your statement that your approach "avoids the historical challenges associated with safely and effectively inhibiting growth factors for therapeutic effect." This statement could imply that your approach is safer and more effective. As efficacy and safety determinations are solely within the FDA's authority, please remove this statement here and in your MD&A and Business overviews.
SRRK answered
For the Staff’s convenience, a table summarizing stock options (or, with respect to the Company’s predecessor, Scholar Rock, LLC, prior to the reorganization of the Company described in the Registration Statement, incentive units) granted between September 27, 2017 and the date hereof, which table reflects the issuance of options to purchase shares of common stock granted by the Company or incentive units granted by the Company’s predecessor, and which the Company has included in the Registration Statement, attached hereto as Exhibit B.
Read in the reply
Our Approach and Proprietary Platform, page 1
SEC asked (3)
Please clarify your discussion and provide more detail about what technology or assets comprise your "proprietary platform" beyond the scientific insights already discussed. Our Pipeline Programs, page 3
SRRK answered
Proposed language that the Company intends to include in a subsequent amendment to the Registration Statement listing the significant factors contributing to any difference between its most recent common stock valuations on September 27, 2017, December 22, 2017 and March 5, 2018, and the midpoint of the estimated price range for this offering (before giving effect to a contemplated reverse stock split of the Company’s common stock in connection with the offering).
Rest of the answer

The Company expects that such disclosure would be generally consistent with the currently contemplated disclosure attached hereto as Exhibit C.

The Company advises the Staff that the general approach taken by the Company in determining the fair value of its common units and common stock, including as of September 27, 2017, which the Company’s board of directors considered for incentive unit grants on September 27, 2017 and October 26, 2017, as of December 22, 2017, which the Company’s board of directors considered for option grants on February 20, 2018 and as of March 5, 2018, which the Company’s board of directors considered for option grants on April 3, 2018 and April 15, 2018, are set forth beginning on page 82 of the prospectus included in the Registration Statement. Additional factors considered in the fair value assessments as of September 27, 2017, December 22, 2017 and March 5, 2018 are described below.

As described in the Registration Statement, the Company estimated the value of its equity using the market approach, including the guideline public company method and a precedent transaction method which ‘‘backsolves’’ to a preferred price. The Company allocated equity value to its common units, incentive units and convertible preferred units or to common stock and convertible preferred stock, as the case may be, using either an option-pricing method (“OPM”) or a hybrid method, which is a hybrid between the OPM and the probability-weighted expected return method. The OPM treats common securities and preferred securities as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company’s securities changes. Under this method, the common units and incentive units and common stock have value only if the funds available for distribution to members or stockholders exceed the value of the preferred security liquidation preference at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method estimates the probability-weighted value across multiple scenarios but uses the OPM to estimate the allocation of value within at least one of the scenarios. In addition to the OPM, the hybrid method considers an initial public offering (“IPO”) scenario in which the shares of convertible preferred stock are assumed to convert to common stock. The future value of the common units, incentive units and common stock in the IPO scenario is discounted back to the valuation date at an appropriate risk adjusted discount rate. In the hybrid method, the present value indicated for each scenario is probability weighted to arrive at an indication of value for the common units, incentive units and common stock.

September 27, 2017 Valuation

The fair value of the Company’s common units of $1.71 per unit at September 27, 2017 was determined by the Company’s board of directors with the assistance of an independent third-party valuation firm. This valuation was used to support the fair value of the Company’s common units with respect to incentive units granted on September 27, 2017 and October 26, 2017. This valuation utilized the hybrid method. The present value of the Company’s common units in an IPO scenario was calculated based on metrics observed from then-recent IPOs of comparable companies, including pre-money IPO valuations and step-ups. The value of the Company’s common units in a remain-private scenario was calculated using the OPM. The valuation assumed a 10% probability of an IPO and a 90% probability of remaining private. A discount for lack of marketability of 15% and 28% was applied to the IPO and remaining private scenarios, respectively.

December 22, 2017 Valuation

The fair value of the Company’s common stock of $2.02 per share at December 22, 2017 was determined by the Company’s board of directors with the assistance of an independent third-party valuation firm. This valuation was used to support the fair value of the Company’s common stock with respect to options granted on February 20, 2018. This valuation utilized the hybrid method. The present value of the Company’s common stock in an IPO scenario was calculated based on metrics observed from then-recent IPOs, including pre-money IPO valuations and step-ups. The value of the Company’s common stock in a remain-private scenario was calculated using the OPM. The valuation assumed a 25% probability of an IPO and a 75% probability of remaining private. A discount for lack of marketability of 18% and 24% was applied to the IPO and remaining private scenarios, respectively.

March 5, 2018 Valuation

The fair value of the Company’s common stock of $2.51 per share at March 5, 2018 was determined by the Company’s board of directors with the assistance of an independent third-party valuation firm. This valuation was used to support the fair value of the Company’s common stock with respect to options granted April 3, 2018 and April 15, 2018. This valuation utilized the hybrid method. The present value of the Company’s common stock in an IPO scenario was calculated based on metrics observed from then-recent IPOs of comparable companies, including pre-money IPO valuations and step-ups. The value of the Company’s common stock in a remain-private scenario was calculated using the OPM. The valuation assumed a 40% probability of an IPO and a 60% probability of remaining private. A discount for lack of marketability of 10% and 29% was applied to the IPO and remaining private scenarios, respectively.

The weighting attributed to the IPO scenarios in each of the valuations above reflected assessments as to the likelihood of an IPO, the uncertainty regarding the Company’s planned commencement of its Phase 1 clinical trial of SRK-015, and the uncertainty concerning whether investors might be receptive to making an investment in the Company. The Company also considered macroeconomic and overall market conditions, including the Company’s subjective assessment of market conditions for IPOs of companies similarly situated to the Company and the Company’s subjective assessment as to the likelihood of successfully executing an IPO in the coming months, among other factors.

The Company respectfully requests that the Staff return to us this letter and the information provided pursuant to Exhibits A, B and C pursuant to Rule 418 of the Securities Act of 1933, as amended, once the Staff has completed its review. We have provided a self-addressed stamped envelope for this purpose. In addition, the Company requests confidential treatment under 17 C.F.R. § 200.83 (1992) for this letter and the information provided pursuant to Exhibits A, B and C of this letter and has submitted a separate request for confidential treatment in accordance therewith to the Commission’s Office of Freedom and Information Privacy Act Operations.

Read in the reply
Our Approach and Proprietary Platform, page 1
SEC asked (4)
Please include columns for Phase 2 and Phase 3 in your product pipeline table.
SRRK answered

No numbered answer found in the reply. Read the reply ↗

Our Approach and Proprietary Platform, page 1
SEC asked (5)
To the extent product candidates and indications for your TGFB1 and BMP6 programs are known please disclose them on your product pipeline table. If you have not yet identified product candidates and indications relating to these programs, it is premature to present these programs on your product pipeline table.
Rest of the question

In this regard, we note your disclosure in the risk factor on page 15 that, other than SRK-015, “[a]ll of our other programs are in preclinical development, and we have yet to nominate a clinical candidate from these programs."

SRRK answered

No numbered answer found in the reply. Read the reply ↗

Use of Proceeds, page 64
SEC asked (6)
We note your disclosure that portions of the proceeds will be allocated to fund research and development activities for SRK-015 and the TGFB1 programs. Please expand your disclosure to include your estimate of how far you expect to reach, in the development process, for each program using the funds raised by the offering. In addition, please tell us why there is no allocation for the BMP6 Program.
SRRK answered

No numbered answer found in the reply. Read the reply ↗

Management's Discussion and Analysis of Financial Condition and Results of Operations · Overview, page 72
SEC asked (7)
Please tell us if your proprietary platform involves a significant software element that should be disclosed in describing how the platform facilitates your activities. Also describe for us how you account for the expenses incurred to develop and maintain your proprietary platform.
SRRK answered

No numbered answer found in the reply. Read the reply ↗

Results of Operations · Comparison of the Years Ended December 31, 2016 and 2017, page 76
SEC asked (8)
Please provide further detail regarding the "performance obligations under the option and license agreement" that were completed in 2016 and the revenue associated with these performance obligations.
SRRK answered

No numbered answer found in the reply. Read the reply ↗

Research and Development, page 76
SEC asked (9)
Please disclose the research and development expenses incurred by program for the periods presented. If you do not separately track certain costs, for example internal costs, by programs, disclose that fact.
SRRK answered

No numbered answer found in the reply. Read the reply ↗

Business · TGFB1 in Fibrosis, page 102
SEC asked (10)
We note your statement that "data suggest that novel approaches for the safe and effective targeting of TGFB signaling may have broad applicability to the treatment of fibrotic disease." As efficacy and safety determinations are solely within the FDA's authority, please remove or further qualify this statement as it appears to reference peer-reviewed studies as the basis for the statement.
Rest of the question

Similarly, please remove or further qualify your statement on page 106 that "liver-selective inhibition of BMP6 signaling could provide a safe and effective way to target a variety of iron-restricted anemias."

SRRK answered

No numbered answer found in the reply. Read the reply ↗

License Agreements · License Agreement with Children's Medical Corporation, page 107
SEC asked (11)
You state that certain "development and regulatory milestone payments" will be paid in the event that you "realize sales from products covered by the license agreement." Please provide more information regarding which products or programs are covered by the license agreement.
SRRK answered

No numbered answer found in the reply. Read the reply ↗

License Agreements · License Agreement with Children's Medical Corporation, page 107
SEC asked (12)
Please provide more detail regarding the "diligence milestones" that the CMCC Agreement obligates you to meet.
SRRK answered

No numbered answer found in the reply. Read the reply ↗

Intellectual Property, page 108
SEC asked (13)
Please disclose whether there are contested proceedings or third-party claims relating to each patent.
SRRK answered

No numbered answer found in the reply. Read the reply ↗

Intellectual Property, page 108
SEC asked (14)
Please disclose whether there are any issued or pending patents or patent families associated with your BMP6 program.
SRRK answered

No numbered answer found in the reply. Read the reply ↗

Intellectual Property, page 108
SEC asked (15)
We note your patent family disclosures regarding Myostatin Activation Inhibitors and TGFB1 Activation Inhibitors. Please clarify whether any of these patents have been issued.
SRRK answered

No numbered answer found in the reply. Read the reply ↗

Intellectual Property, page 108
SEC asked (16)
We note your disclosure regarding issued patents associated with your platform. Please provide more detail regarding the patents cited and how they relate to your platform. Please also expand your disclosure regarding your platform, and the patents associated with TGFB1, to discuss the type of protection (e.g., composition of matter, use, or process) you have under these patents.
SRRK answered

No numbered answer found in the reply. Read the reply ↗

General
SEC asked (17)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
SRRK answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary · Our Pipeline Programs, page 2
SEC asked
We note your response to comment 5. We continue to believe that it may be premature to include the TGFB1 and BMP6 programs on your pipeline table. You have not identified any anticipated milestones for your BMP6 program and your TGFB1 program's anticipated milestone appears to be too remote for reasonable inclusion on the pipeline table.
Rest of the question

We also note that three of your targets within the TGFB1 program are only in the discovery stage of development. Additionally, the indications that you have identified appear to be the general therapeutic areas that your targets have applicability within and do not necessarily appear to evince the level of specificity that you have described for SRK-015. While it may be appropriate to discuss and describe these programs elsewhere in your filing, we do not believe that it is appropriate to include these programs on your Prospectus Summary pipeline table at this time.

SRRK answered
The Company respectfully advises the Staff that it has modified its disclosure on pages 3 and 95 to remove its pipeline table from Amendment No. 1.
Read in the reply

Also in this review: company letter, May 21, 2018, company letter, May 21, 2018

Letters without questions

Other letters

UPLOAD and CORRESP
4 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 10 letters filed since 2018-04-19. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SRRK/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.